ABO blood group relationships to kidney transplant recipient and graft outcomes.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 26 04 2020
accepted: 05 07 2020
entrez: 24 7 2020
pubmed: 24 7 2020
medline: 25 9 2020
Statut: epublish

Résumé

Certain ABO blood types have been linked to cardiovascular disease, infection and cancers. The effect of recipient ABO blood group on patient and graft survival has not been studied in ABO-matched kidney transplantation. This study aims to determine the association between kidney transplant recipient ABO blood groups with patient and graft survival in Australian and New Zealand. All Australian and New Zealand transplant recipients who received ABO-compatible primary kidney transplants between 1995-2016 were analysed using a de-identified dataset from the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. Primary analysis was undertaken of recipient ABO blood group O versus non-O blood groups. The primary outcome was patient survival post kidney transplantation and the secondary outcome was death censored graft survival. Recipient age at first transplant, gender, ethnicity, body mass index, smoking status, vascular disease, presence of diabetes mellitus, chronic lung disease, primary kidney disease, donor source, donor age and gender, and era of transplants were included in the multivariate model as confounders. On analysis of 15,523 kidney transplant recipients, blood group O was not associated with patient survival (hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.89-1.04) nor death censored graft survival (HR 0.97, 95% CI 0.89-1.05) compared to non-blood group O recipients. Competing risks analyses showed an increased risk of cancer-related mortality in blood group O recipients on univariate analyses (HR 1.18, 95% CI 1.01-1.37) however, this became insignificant on multivariate analyses. On secondary analyses, recipient blood group AB (4.11% participants) was associated with inferior death censored graft survival compared to those with blood group O (HR 1.24, 95% CI 1.02-1.50). Although recipient ABO blood groups were not associated with patient nor graft survival, differences in cause-specific mortality between individual blood groups cannot be excluded based on current analyses.

Identifiants

pubmed: 32702043
doi: 10.1371/journal.pone.0236396
pii: PONE-D-20-12070
pmc: PMC7377395
doi:

Substances chimiques

ABO Blood-Group System 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0236396

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Am Soc Nephrol. 2005 Nov;16(11):3437-44
pubmed: 16176999
J Surg Oncol. 1986 Sep;33(1):24-6
pubmed: 3093776
J Urol. 1987 Oct;138(4):758-9
pubmed: 3656526
Clin Chem Lab Med. 2013 Aug;51(8):1545-53
pubmed: 23648637
BMC Nephrol. 2019 Mar 28;20(1):107
pubmed: 30922296
Crit Rev Clin Lab Sci. 2012 Jul-Aug;49(4):137-49
pubmed: 22856614
PLoS One. 2010 Aug 04;5(8):e11972
pubmed: 20694147
Transfus Med Rev. 2000 Oct;14(4):291-301
pubmed: 11055074
Blood Transfus. 2013 Oct;11(4):491-9
pubmed: 24120598
J Thromb Thrombolysis. 2014;38(2):160-6
pubmed: 24233389
Kidney Int. 2000 Sep;58(3):1311-7
pubmed: 10972695
Transplantation. 2006 Oct 15;82(7):882-6
pubmed: 17038901
Baillieres Clin Haematol. 1993 Jun;6(2):465-92
pubmed: 8043935
J Am Soc Nephrol. 2006 Jul;17(7):2056-68
pubmed: 16775031
J Urol. 2014 May;191(5):1238-43
pubmed: 24333243
Iran J Kidney Dis. 2011 Jul;5(3):141-8
pubmed: 21525572
J Am Soc Nephrol. 2019 Feb 14;:
pubmed: 30765426
Clin Microbiol Rev. 2015 Jul;28(3):801-70
pubmed: 26085552
Ann Hematol. 2004 Sep;83(9):584-7
pubmed: 15175895
Transfus Med Rev. 2012 Apr;26(2):103-18
pubmed: 21945157
Nephrol Dial Transplant. 1997 Aug;12(8):1672-9
pubmed: 9269647
Transplantation. 2008 Mar 27;85(6):844-9
pubmed: 18360266
Wiley Interdiscip Rev Syst Biol Med. 2016 Nov;8(6):517-535
pubmed: 27599872
Am J Nephrol. 2014;40(4):315-24
pubmed: 25341624
Lancet Diabetes Endocrinol. 2017 Jan;5(1):26-33
pubmed: 28010785
Am J Nephrol. 1998;18(2):89-95
pubmed: 9569948
Nephrology (Carlton). 2004 Dec;9 Suppl 4:S138-43
pubmed: 15601406
J Am Soc Nephrol. 2004 Apr;15(4):1086-91
pubmed: 15034113
Blood. 2008 Apr 1;111(7):3540-5
pubmed: 18245665
Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33
pubmed: 18701615
Immunohematology. 2009;25(2):48-59
pubmed: 19927620
PLoS One. 2015 Apr 13;10(4):e0122856
pubmed: 25874862

Auteurs

Monica S Y Ng (MSY)

Kidney Health Service, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

Shahid Ullah (S)

Australia and New Zealand Dialysis and Transplant Registry, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.

Gregory Wilson (G)

The Department of Nephrology, The Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

Stephen McDonald (S)

Australia and New Zealand Dialysis and Transplant Registry, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.

Matthew Sypek (M)

Australia and New Zealand Dialysis and Transplant Registry, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Andrew J Mallett (AJ)

Kidney Health Service, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH